RPG Life Sciences share price today

RPG Life Sciences Ltd's share price was ₹2,553.70 at the close on 6 November 2026. It has been rising for 20 weeks. That is 1.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,865 and ₹3,051, and at that close it sat 58% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today RPG Life Sciences Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.

Over the last 11 years the share price moved +920% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Indian funds and insurers (DIIs) raised their stake for 14 quarters in a row

   From 0.1% to 9.9% of the company by the September 2026 quarter.

3. Revenue up on a year earlier for 9 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹193 crore, +6% on a year earlier.

   Why: Revenue was higher because all three parts of the business grew. The domestic business sold more, the active ingredient business did better, and international sales grew again.

   Next results: check whether domestic sales get back to their earlier pace after the stock and supply issues.

   From the earnings call on 30 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), RPG Life Sciences reported revenue of ₹193 crore, up 6.0% from ₹182 crore a year earlier, and a profit of ₹23.0 crore, down 37.8% from ₹37.0 crore.

RPG Life Sciences results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

RPG Life Sciences' management discussed these results on a call held on 30 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

RPG Life Sciences closed at ₹2,553.70 on 6 November 2026, up 6.4% from ₹2,400.40 a year earlier (7 November 2025) and up 261.1% over five years. Its highest weekly close since March 2016 was ₹3,050.60 on 25 September 2026.

RPG Life Sciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 6 November 2026.

6 Nov 2026: RPG Life Sciences closed at ₹2,553.70, down 0.9% on the week and down 6.1% on the month. 30 Oct 2026: RPG Life Sciences held its results call for July to September 2026. Management guided: Acquired API H2 revenue ₹25 crore to ₹30 crore at mid-20s operating margin in line with existing base.

Earlier

• Results for July to September 2026: Revenue up 6.0% and profit down 37.8% on a year earlier.
• 9 Jul 2026: ex-date for a dividend of ₹24 a share.

RPG Life Sciences paid ₹24 a share in regular dividends in the 12 months to 7 November 2026 (1 payment), a yield of 0.94% at the ₹2,553.70 close on 6 November 2026. The last was a dividend of ₹24 a share, ex-date 9 July 2026.

RPG Life Sciences dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. RPG Life Sciences Ltd paid out 34% of its profit as dividends in FY26, and it paid a dividend in each of its last 12 reported years.

From the NSE corporate-actions record, read 7 November 2026.

On the call for July to September 2026, held on 30 October 2026, RPG Life Sciences' management guided: Acquired API H2 revenue ₹25 crore to ₹30 crore at mid-20s operating margin in line with existing base.

Ashok Nair, on the call for July to September 2026

What management guided

• API organic double-digit with combined at least 30% yearly growth over 3 to 5 years to ₹300-350 crore by FY30 and ₹500 crore by FY32.
• Domestic Formulations above 1.5 times market growth with Q3 rebound to prior momentum.
• International Formulations double-digit growth from H2 on stronger order pipeline and tender execution.
• Chile and Ethiopia tenders about ₹10 crore from FY29 plus UK CDMO about ₹8 crore from FY29.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 30 October 2026.

When RPG Life Sciences reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Domestic reported growth rebounds to flagged pace in Q3 with normalized stock and resolved supply.

RPG Life Sciences is on one of our India lists: Pharma stocks.

RPG Life Sciences Ltd earned ₹23.0 Cr of net profit in the Sep 2026 quarter, −37.8% on the same quarter a year earlier. Full-year FY26 profit was ₹115 Cr. Over 10 years profit has grown 25.4% a year on average. That is 11.9% of the quarter's revenue. The same quarter a year earlier earned ₹37.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹115 Cr (−37.2% on the year before).

Why profit moved: revenue changed +6.0% on a year earlier and the margin moved −4.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −32.5% and revenue +12.4%. Profit is growing slower than sales: rising costs are taking part of the growth.

RPG Life Sciences Ltd reported ₹193 Cr of revenue in the Sep 2026 quarter, +6.0% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 9.8% a year on average. The last full year, FY26, came in at ₹708 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹746 Cr.

FY26 revenue was ₹708 Cr, +8.4% on the year before.

Recent pace: the last four quarters grew +12.4% on average, against 9.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +11.8%, against +9.9% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −50.7%, against +23.1% a year (rolling over).

RPG Life Sciences Ltd's operating margin was 17.0% in the Sep 2026 quarter, 4.0 percentage points lower than the same quarter a year ago. Across 12 years it has been between 6.0% and 25.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −4.6 percentage points on the year while gross margin changed +0.3 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 59% of RPG Life Sciences Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹56.0 Cr of operating cash against ₹115 Cr of profit. After ₹53.0 Cr of spending on assets, ₹3.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 59% of profit came in as cash: the cash cycle got 15 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 15 days longer. The next section looks at where the cash is stuck.

RPG Life Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 99 days in FY26, up from 84 days in FY21. It spent ₹130 Cr on assets over the last 3 years. Customers take 60 days to pay, and stock sits for 179 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹708 Cr, each day of that cycle ties up about ₹1.9 Cr, so roughly ₹192 Cr is tied up in the business at any time.

FY26: customers took 60 days to pay and stock sat for 179 days, about 5.9 months of sales sitting as stock, for a full cycle of 99 days, longer than FY21's 84.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 179 days. Customers pay about 60 days after that. Suppliers are paid at 141 days. Together that makes the 99-day cycle.

Spending on assets: ₹130 Cr over the last 3 years, against ₹59.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹23.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

RPG Life Sciences Ltd's P/E is 37.9×, near the high end of its own history: higher than 77% of past readings. Its usual P/E (the middle reading) is 30.1×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹64.02.